Open-Label Extension and Safety Study of Talazoparib
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02921919
- Collaborators
- Medivation, Inc.
- Investigators
- Study Director: Pfizer Pfizer CT.gov Call Center Pfizer
Get Well Soon